Altered Cytokine Profile in Clinically Suspected Seronegative Autoimmune Associated Epilepsy

Area of Science:

• Neuroimmunology
• Epileptology
• Biomarker Discovery

Background:

• Autoimmune-associated epilepsy (AAE) is a growing cause of drug-resistant epilepsy, often treated with immunotherapy.
• Current diagnosis relies on detecting neuronal autoantibodies, missing cases like seronegative AAE (snAAE) that respond to treatment.
• Identifying biomarkers for snAAE is crucial for accurate diagnosis and effective treatment.

Purpose of the Study:

• To identify novel diagnostic biomarkers for snAAE.
• To compare cytokine and autoantibody profiles in snAAE, anti-seizure medication (ASM)-responsive epilepsy, and other neuroinflammatory diseases.

Main Methods:

• Comprehensive analysis of cytokines and autoantibodies in patient cohorts.
• Comparison of biomarker profiles between snAAE, ASM-responsive epilepsy, and neuroinflammatory disease groups.

Main Results:

• A unique signature of 14 elevated cytokines was identified in snAAE patients.
• Specific cytokines like IL-6, IL-8, IL-10, VEGF-A, and TNF-b were highlighted as potential snAAE biomarkers.
• Autoantibody screening did not identify specific targets in snAAE, but ASM-responsive epilepsy showed increased autoantibodies against brain plasma membrane proteins.

Conclusions:

• Cytokine analysis, rather than expanded autoantibody screening, offers a promising diagnostic approach for snAAE.
• Identifying immune dysregulation through cytokine profiling can facilitate immunotherapy trials for AAE patients.
• ASM-responsive epilepsy may involve immune hyperactivity independent of seizure control, suggesting potential for disease progression independent of seizure activity (PISA).